Analysis: Falling demand for COVID boosters makes price hikes more likely

With fewer shots needed, vaccine makers including Pfizer Inc , partner BioNTech SE , rival Moderna Inc (MRNA.O) and Novavax Inc (NVAX.O) could have to hike prices as much as three times current levels if they hope to meet Wall Street revenue forecasts for the shots for 2023 and beyond, several analysts said.

 

...A recent poll by Kaiser Family Foundation found that two-thirds of American adults do not plan on getting a COVID vaccine soon. Analysts are expecting the U.S. market to be as low as one-third the size of the flu.

...